PROCEPT BioRobotics is a growth-stage medical robotics company posting 20% revenue growth but in a confirmed falling-knife technical setup with a death cross, momentum score of only 3.0, volume surges on selloffs, and below-floor quality at 3.2 out of 10, making it a high-risk situation despite 30% analyst upside to target.
Thesis pillars
- Falling Knife Technical Setup→Stable
- Revenue Growth Moat Foundation→Stable
- Cash Burn Below Quality Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
PROCEPT BioRobotics Corporation (PRCT) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $20.73: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.17; Below-average business quality.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally... Read more
Sell if holding. Engine safety override at $20.73: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.17; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Score 5.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — PROCEPT BioRobotics Corporation
Latest news
- NEWS This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday — benzinga Jun 24, 2026 positive
- NEWS This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday — benzinga Jun 24, 2026 positive
- NEWS Evercore ISI Group Initiates Coverage On PROCEPT BioRobotics with Outperform Rating, Announces Price Target of $30 — benzinga Jun 24, 2026 positive
- NEWS Top 3 Health Care Stocks You'll Regret Missing In Q2 — benzinga Jun 18, 2026 neutral
- NEWS This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday — benzinga Jun 11, 2026 neutral
Generated 2026-07-06T03:20:33Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -31.8%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.73: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.17; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Prior stop was $19.56. Score 5.3/10, moderate confidence.
Take-profit target: $26.27 (+24.9% upside). Prior stop was $19.56. Stop-loss: $19.56.
Quality below floor (3.2 < 4.0).
PROCEPT BioRobotics Corporation trades at a P/E of N/A (forward -24.2). TrendMatrix value score: 7.6/10. Verdict: Sell.
21 analysts cover PRCT with a consensus score of 3.9/5. Average price target: $30.
What does PROCEPT BioRobotics Corporation do?PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the...
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.